Hard No
1 The study details 800 participants in the interim analysis (1,197 total enrolled) with biopsy-confirmed MASH and moderate to severe fibrosis (stage F2 or F3) Participants were randomly assigned to receive semaglutide 2.4 mg weekly or placebo Treatment lasted 72 weeks 2:1 randomisation (534 semaglutide, 266 placebo) Resolution of MASH (primary outcome) Fibrosis improvement (primary outcome) Combined outcomes About a third (32.7%) of participants taking semaglutide achieved both MASH resolution and fibrosis improvement, compared to 16.1% on placebo
Guo T, Yan W, Cui X, Liu N, Wei X, Sun Y, et al
53 In another more recent study, IV glutathione prevented the increase in oxidative stress markers while oral NAC (N-acetyl cysteine), an amino acid needed to make glutathione, had no effect
Theoretically, 2.5 mg of semaglutide would equal approximately: 368 units at 0.68 mg/mL concentration (2.5 mg 0.68 mg/mL 100) 187 units at 1.34 mg/mL concentration (2.5 mg 1.34 mg/mL 100) 93 units at 2.68 mg/mL concentration (2.5 mg 2.68 mg/mL 100) However, these calculations are purely theoretical
This will be our next objective